Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
Public ClinicalTrials.gov record NCT00282087. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Adjuvant Treatment of High Risk Uterine Leiomyosarcoma With Gemcitabine/Docetaxel Followed by Doxorubicin: A Phase II Trial
Study identification
- NCT ID
- NCT00282087
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Sarcoma Alliance for Research through Collaboration
- Other
- Enrollment
- 47 participants
Conditions and interventions
Conditions
Interventions
- gemcitabine, docetaxel, doxorubicin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2005
- Primary completion
- Dec 31, 2011
- Completion
- Dec 31, 2011
- Last update posted
- Nov 30, 2014
2006 – 2012
United States locations
- U.S. sites
- 12
- U.S. states
- 11
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Washington Cancer Institute/Washington Hospital Center (Medstar) | Washington D.C. | District of Columbia | 20010 | — |
| H. Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | — |
| Winship Cancer Institute at Emory University | Atlanta | Georgia | 30308 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| St. Vincent Gynecologic Oncology | Indianapolis | Indiana | 46260 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 01225 | — |
| Massachusetts General | Boston | Massachusetts | 02114 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Nebraska Methodist Hospital | Omaha | Nebraska | 68114 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10021 | — |
| Pennsylvania Oncology Hematology Associates | Philadelphia | Pennsylvania | 19106 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00282087, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 30, 2014 · Synced May 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00282087 live on ClinicalTrials.gov.